U.S. FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™
Pfizer
DECEMBER 20, 2022
FDA Extends Review of Pfizer’s New Drug Application for PAXLOVID™. Tuesday, December 20, 2022 - 04:30pm. Pfizer oral treatment remains available to eligible U.S. patients under Emergency Use Authorization as a critical tool in the fight against COVID-19. NEW YORK, December 20, 2022 -- Pfizer Inc. NYSE: PFE) announced today that the U.S. In the U.S.,
69 
Let's personalize your content